San Francisco Amprion, a leader in diagnostics for neurodegenerative diseases, invites researchers and practitioners attending MDS to visit Amprion at booth #212. We look forward
Amprion is pleased to announce a research collaboration with Mayo Clinic in Florida to investigate biomarker utility within the cerebrospinal fluid (CSF) from patients with
Thanks to additional research funding from NIH/NINDS, Amprion joins the world’s heightened focus during Alzheimer’s & Brain Health Awareness Month by expanding its quantitative study
For the first time in history, Amprion’s breakthrough SYNTapÒ Biomarker Test can help doctors effectively distinguish Parkinson’s Disease (PD) from Parkinsonism early. This innovative test
We invite AAN Annual Meeting attendees to visit Amprion’s booth #1074 and meet our CEO/Co-Founder and clinical director. Explore the science behind the SYNTapⓇ Biomarker
A rapidly aging nation, the U.S. has 60 million people aged 65 and older. Of these, about 12 million people show early symptoms of Mild
Amprion Clinical Laboratory Receives Accreditation From College Of American Pathologists San Francisco, CA / Oct. 27th, 2021—Amprion announces that The Accreditation Committee of the College
SYNTap™ Test Announcement Breakthrough biomarker test aids physicians in diagnosing synucleinopathies by detecting misfolded Synuclein aggregates in cerebrospinal fluid (CSF). Alpha-Synuclein is a misfolded protein
For Immediate Release May 22, 2019 Amprion Joins the Fight Against Parkinson’s Through Early Detection Testing FDA Grants Breakthrough Device Designation For Amprion’s PMCA
A pioneer in the science of detecting mis-folded proteins, Amprion advances the diagnosis of brain disorders. Our SYNTap™️ Biomarker Test aids physicians in diagnosing Parkinson’s, Lewy Body Dementia, and Alzheimer’s with Lewy Body variant. We plan to launch more biomarker tests in the future.
